NYSE
43.33USD
-1.05 (-2.37%)
We have scored 35 news catalysts on Qiagen N.V. (QGEN) over the past 12 months. The biggest single-day move next to one of them came Mar 9, 2026, when QGEN closed −2.7%: “Ongoing Grocery Outlet Holding Corp. (GO) Investigation: Protect Your Rights - Contact Levi & Korsinsky”. Coverage across the window leans negative (average ticker sentiment −0.25). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
8.9B
P/E
—
EPS
—
Beta
0.63
52W range
32.53-57.82
Day range
43.32–44.31
Open
44.30
Prev close
44.38
Volume
1.7M
Avg volume
2.7M
Dividend
2.64
IPO
1996-06-28
Analysts publish price targets on QGEN, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
7 analyst price targets from $36 to $48
as of 2026-09-02
The market is 8% above the median target — more optimistic than the analysts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Qiagen N.V. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for QGEN: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
The reconstruction
The price sits 8% above the median published target and at the 71st percentile by count, meaning it leans bullish against the analyst set and already pays for the second-half sales acceleration management promised.
What the disagreement turns on
Whether QuantiFERON demand and China sales actually accelerate as the second half unfolds, which can be tested with wired segment revenue data but cannot resolve the overhanging fraud investigation.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
